Search

everythinglearnresearchcommunity

for

Search:↓

New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.

Genetic variants in CYP genes may worsen PCOS symptoms.

Vitamin D has potential benefits for cancer prevention, heart health, diabetes, obesity, muscle function, skin health, and immune function, but clinical results are mixed and more research is needed.

New treatments for male hypogonadism are effective and should be personalized.

Antiandrogens, particularly flutamide and CPA, are most effective for treating hirsutism, with long-term use needed for best results.

Vimentin is crucial for wound healing, cell growth, and managing immune responses.

Women with PCOS have higher 5alpha-reductase activity, affecting steroid levels.

Ovarian SAHA syndrome makes women with PCOS more resistant to insulin and increases their risk of blood sugar problems.

Mice without the vitamin D receptor gene lose hair due to disrupted hair follicle cycles.

Antiandrogens can treat female hormonal conditions, but environmental ones may harm reproductive health.

Understanding drug interactions, side effects, and patient-specific factors is crucial for effective dermatological care.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

The document concludes that early recognition and treatment of PCOS in adolescents is crucial for managing symptoms and long-term health risks.

PCOS affects women's health by increasing the risk of diabetes, heart disease, and reproductive issues.

Adrenal disorders can cause lasting brain and behavior issues in children.

Higher BMI links to worse hair loss in Taiwanese men.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

The document concludes that managing hirsutism involves identifying the cause, using a scoring system for severity, combining cosmetic and medical treatments, encouraging weight loss, and providing psychological support, while noting the need for more research on drug treatments.

Recent genetic insights show that low-renin hypertension includes a range from essential hypertension to secondary or familial forms, affecting diagnosis and treatment.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

Finasteride and dutasteride reduce neurosteroid production, possibly helping treat glioblastoma.

Effective hirsutism management requires identifying the cause, combining new and traditional treatments, and setting realistic expectations for patients.

The conclusion is that while oral contraceptive pills are effective for PCOS-related high androgen levels, new treatments with fewer side effects are needed.

Differentiating PCOS from NCAH helps improve diagnosis and treatment.

The chapter explains the causes of excessive hair growth and masculinization in women and how to measure hormone levels related to these conditions.

Female pattern hair loss involves thinning hair on crown and frontal scalp, diagnosed by hair ratio, and treated with minoxidil, antiandrogens, or hair transplantation.

Diagnosing sex development disorders requires combining medical history, physical exams, imaging, lab tests, and genetic data.

Plasma protein binding significantly affects glucocorticosteroid concentration in blood, saliva, and hair.

The document concludes that accurate diagnosis of male and female gonadal disorders is crucial for effective treatment and better patient outcomes.